Outlook Therapeutics, Inc. (OTLK): Nasdaq/NYSE listing notice — Outlook Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure

Outlook Therapeutics, Inc.

Stock closed below $1.00 for 32 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
180-day compliance period ends April 15, 2024; must close at $1.00 for 10 consecutive business days.
If not cured, company may be eligible for another 180-day period if it meets other listing standards.
Company intends to monitor bid price and evaluate options, including reverse stock split.
Failure to regain compliance could lead to delisting from Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Outlook Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 16, 2023, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accorda

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-110537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.